William Blair Investment Management LLC Makes New Investment in ICU Medical, Inc. $ICUI

Key Points

• William Blair Investment Management initiated a position in ICU Medical worth approximately $25.2 million, while institutional investors collectively own 96.1% of the company’s stock.
• ICU Medical reported quarterly EPS of $2.37, beating estimates of $1.91, and revenue of $547.9 million versus expectations of $533.4 million. The company issued fiscal 2026 EPS guidance of $8.60–$9.00.
• The stock recently traded at $182.84, near its 52-week high, with analysts maintaining a consensus “Moderate Buy” rating and an average price target of $192.80; insiders have sold about $3.1 million in shares over the past 90 days.

William Blair Investment Management LLC bought a new position in shares of ICU Medical, Inc. (NASDAQ:ICUI - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 172,181 shares of the medical instruments supplier's stock, valued at approximately $25,242,000. William Blair Investment Management LLC owned approximately 0.69% of ICU Medical as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. BlackRock Inc. purchased a new position in shares of ICU Medical in the second quarter worth about $550,250,000. Vanguard Group Inc. grew its stake in ICU Medical by 3.4% during the 4th quarter. Vanguard Group Inc. now owns 2,714,746 shares of the medical instruments supplier's stock valued at $387,313,000 after acquiring an additional 89,755 shares in the last quarter. Janus Henderson Group PLC raised its holdings in ICU Medical by 3.9% in the 1st quarter. Janus Henderson Group PLC now owns 2,676,012 shares of the medical instruments supplier's stock valued at $345,607,000 after acquiring an additional 99,256 shares during the last quarter. Millennium Management LLC raised its holdings in ICU Medical by 173.4% in the 3rd quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier's stock valued at $130,638,000 after acquiring an additional 690,694 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in ICU Medical by 6.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 983,802 shares of the medical instruments supplier's stock worth $127,053,000 after purchasing an additional 63,026 shares in the last quarter. Hedge funds and other institutional investors own 96.10% of the company's stock.

ICU Medical Trading Up 0.2%

NASDAQ ICUI opened at $182.84 on Friday. The firm's 50-day moving average is $160.85 and its two-hundred day moving average is $143.13. ICU Medical, Inc. has a 12 month low of $112.50 and a 12 month high of $192.85. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.43 and a quick ratio of 1.21. The stock has a market capitalization of $4.57 billion, a P/E ratio of 154.95, a PEG ratio of 2.31 and a beta of 0.74.

ICU Medical (NASDAQ:ICUI - Get Free Report) last announced its earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.46. The company had revenue of $547.88 million during the quarter, compared to analyst estimates of $533.44 million. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. ICU Medical's revenue was up .5% compared to the same quarter last year. During the same quarter last year, the firm posted $2.10 earnings per share. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. On average, sell-side analysts anticipate that ICU Medical, Inc. will post 7.19 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on ICUI shares. Wall Street Zen upgraded ICU Medical from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 8th. Raymond James Financial reaffirmed a "strong-buy" rating and issued a $200.00 price target on shares of ICU Medical in a report on Friday, August 7th. Zacks Research downgraded ICU Medical from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 28th. Weiss Ratings raised ICU Medical from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Thursday, July 23rd. Finally, Needham & Company LLC upped their target price on ICU Medical from $165.00 to $187.00 and gave the company a "buy" rating in a report on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $192.80.

Insider Activity at ICU Medical

In other ICU Medical news, Director Elisha W. Finney sold 378 shares of the business's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $182.48, for a total value of $68,977.44. Following the sale, the director owned 4,871 shares of the company's stock, valued at $888,860.08. The trade was a 7.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Daniel Woolson sold 5,417 shares of the company's stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $181.33, for a total value of $982,264.61. Following the transaction, the vice president owned 17,062 shares in the company, valued at $3,093,852.46. This trade represents a 24.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 16,974 shares of company stock worth $3,085,844. Company insiders own 2.10% of the company's stock.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source